Kamada Ltd (NASDAQ: KMDA)

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic CIK: 0001567529
Add ratio to table...

About

Kamada Ltd., or KMDA, is a global biopharmaceutical company operating in the specialty plasma-derived and biopharmaceutical markets. Its main business activities involve the development, manufacturing, and commercialization of plasma-derived biopharmaceutical products, as well as the distribution of pharmaceutical products in Israel. The company generates revenue through the sale of its proprietary products, which include KEDRAB, CYTOGAM, VARIZIG, WINRHO SDF, HEPGAM B, and GLASSIA. These products are used to treat rare and serious conditions such...

Read more

Investment thesis

Bull case

  • Kamada’s diversified portfolio—spanning anti‑rabies immunoglobulin KedRAB, CMV immunoglobulin Cytogam, the inhaled alpha‑1 antitrypsin (AAT) candidate, and a growing biosimilar pipeline—has produced an 11 % revenue increase and a 35 % rise in adjusted EBITDA over the first nine months of 2025. The company’s ability to maintain double‑digit profitability growth while expanding product mix demonstrates operational resilience and efficient cost management. Management’s reiteration of a 2025 revenue guidance of $178‑$182 million and EBITDA guidance of $40‑$44 million indicates confidence in continued scale, driven by the steady supply agreements and growing sales in both the United States and emerging international markets.
  • The strategic four‑pillar growth plan—organic commercial expansion, business development and M&A, plasma collection, and AAT therapy development—offers multiple, non‑overlapping revenue streams. The plasma centers in Houston and San Antonio are projected to each generate $8‑$10 million in sales at full capacity, and their planned peak capacity of 50,000 liters per year places Kamada among the largest specialty plasma collectors in the U.S. This vertical integration not only provides a stable supply for existing product lines but also creates a new, high‑margin business that can be leveraged for future product launches.
  • The long‑term supply agreement with Kedrion, extending to 2031, secures a steady source of KedRAB revenue and mitigates market concentration risk in the U.S. market. The firm’s strong market share in Canada, Latin America, and selected Asian markets indicates a global expansion trajectory that can be accelerated through targeted marketing and localized distribution partnerships. The firm’s commitment to expanding sales of Glacia in Latin America and the CIS region, combined with a projected royalty income stream from Takeda, provides a predictable, low‑cost revenue base that can cushion the company against volatility in any single therapeutic segment.
  • Cytogam’s SHIELD trial addresses a critical unmet need—late‑onset CMV disease in kidney transplant recipients—by extending the product’s therapeutic window beyond initial prophylaxis. Even though enrollment is currently 60‑65 %, the trial’s design and the collaboration with key opinion leaders provide a robust scientific foundation that could translate into a significant market expansion if positive results materialize. The study’s potential to broaden Cytogam’s indication could drive incremental sales growth, especially as transplant volumes rebound and clinicians seek evidence‑based solutions for late‑CMV management.
  • The inhaled AAT Phase III INNOVATE trial, with an enrollment goal of 180 subjects and a planned interim futility analysis by year‑end, represents a pivotal catalyst that could position Kamada as a first‑in‑class therapy for alpha‑1 antitrypsin deficiency (AATD). Should the futility analysis signal a favorable probability of success, the company can accelerate recruitment and bring the trial to completion, potentially delivering positive top‑line data by H1 2029. A successful AAT therapy would tap into a sizable orphan disease market with high reimbursement potential and limited competitive options, offering a significant upside beyond the current portfolio.
Read more

Bear case

  • Despite the company’s optimistic guidance, several critical risks remain unaddressed or only superficially discussed during the Q&A, raising uncertainty about whether the projected growth will materialize. Management’s responses to questions about Cytogam’s sales performance were vague, citing “inventory management” and “fewer transplants” without providing concrete data or timelines, which could indicate weaker-than-expected demand for the product and a potential drag on revenue growth. The firm’s current reliance on a single supplier network for specialty plasma, combined with the need for multiple backup suppliers, exposes it to supply chain disruptions that could constrain product availability and increase costs.
  • The SHIELD trial’s enrollment rate—60‑65 % of the target—combined with the projected 2029 top‑line data release points to a significant lag before any potential commercial benefit can be realized. Given the highly competitive CMV treatment landscape, any delays or negative outcomes in the trial could result in the product failing to gain traction, eroding the company’s projected sales trajectory. Furthermore, the reliance on an investigator‑initiated study with an unblinded DSMB raises questions about the trial’s robustness and the risk of early termination due to efficacy concerns.
  • The inhaled AAT Phase III trial faces similar temporal challenges, with a two‑year treatment period and a projected top‑line release in 2029. The trial’s interim futility analysis, scheduled for year‑end, will likely result in a no‑go decision if the data are underwhelming, forcing the company to absorb significant R&D expenditures without any near‑term revenue upside. The company’s current guidance does not appear to account for a potential cancellation or failure of this trial, leaving a sizeable portion of its growth narrative exposed to clinical risk.
  • While the company projects significant revenue from its plasma collection centers, it has not yet achieved specialty plasma collection at full capacity, relying instead on external suppliers for most of its product supply. The need to secure FDA approval for the San Antonio site and EMA approvals for both sites introduces regulatory uncertainty that could delay revenue realization. Moreover, the capital expenditure required to bring these sites to full operational status is substantial, potentially eroding the high margins associated with specialty plasma products.
  • The firm’s biosimilar strategy, though promising, has yet to demonstrate substantial impact on top‑line revenue beyond the modest $2.5 million contribution in 2025. The addition of only two more products in the coming months suggests a limited pipeline depth, raising concerns about whether biosimilars can sustain long‑term growth, especially as competition intensifies from larger global biologics companies entering the Israeli market. A shallow pipeline may also limit the firm’s ability to offset declining revenues from its core immunoglobulin products.
Read more

Attribution of expenses by nature to their function [axis] Breakdown of Revenue (2025)

Peer comparison

Companies in the Drug Manufacturers - Specialty & Generic
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 TAK Takeda Pharmaceutical Co Ltd 202.50 Bn 40.69 6.74 27.43 Bn
2 ZTS Zoetis Inc. 51.58 Bn 19.29 5.45 9.04 Bn
3 TEVA Teva Pharmaceutical Industries Ltd 32.45 Bn 22.85 1.88 16.81 Bn
4 UTHR UNITED THERAPEUTICS Corp 26.06 Bn 19.51 8.19 -
5 ACB Aurora Cannabis Inc 15.01 Bn 93.81 -2,482.90 0.04 Bn
6 NBIX Neurocrine Biosciences Inc 12.80 Bn 26.69 4.47 -
7 HCM HUTCHMED (China) Ltd 12.21 Bn 26.85 22.27 0.09 Bn
8 ELAN Elanco Animal Health Inc 11.64 Bn -49.87 2.47 4.02 Bn